These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 17306602

  • 1. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A, Umezawa K, Bonavida B.
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [Abstract] [Full Text] [Related]

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N.
    Int J Oncol; 2006 Apr 01; 28(4):923-30. PubMed ID: 16525642
    [Abstract] [Full Text] [Related]

  • 5. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 01; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ.
    Katsman A, Umezawa K, Bonavida B.
    Curr Pharm Des; 2009 Sep 01; 15(7):792-808. PubMed ID: 19275643
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 01; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Aug 01; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec 01; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 12. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M.
    Clin Cancer Res; 2005 Aug 01; 11(15):5590-4. PubMed ID: 16061877
    [Abstract] [Full Text] [Related]

  • 13. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y, Kizaki M.
    Leuk Res; 2007 Nov 01; 31(11):1529-35. PubMed ID: 17466373
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.
    Matsumoto G, Muta M, Umezawa K, Suzuki T, Misumi K, Tsuruta K, Okamoto A, Toi M.
    Int J Oncol; 2005 Nov 01; 27(5):1247-55. PubMed ID: 16211219
    [Abstract] [Full Text] [Related]

  • 15. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 16. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
    Urology; 2010 Apr 27; 75(4):805-12. PubMed ID: 20156648
    [Abstract] [Full Text] [Related]

  • 17. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
    Horie R, Watanabe T, Umezawa K.
    Drug News Perspect; 2006 May 27; 19(4):201-9. PubMed ID: 16823495
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
    Togano T, Sasaki M, Watanabe M, Nakashima M, Tsuruo T, Umezawa K, Higashihara M, Watanabe T, Horie R.
    Biochem Biophys Res Commun; 2009 Dec 04; 390(1):60-4. PubMed ID: 19778522
    [Abstract] [Full Text] [Related]

  • 20. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K.
    Biomed Pharmacother; 2011 Jul 04; 65(4):252-9. PubMed ID: 21723080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.